Alternate Health Club Review: What Payment Starts—and What Its Terms Leave Open

At Alternate Health Club, the important contract moment comes before a prescription: its semaglutide page says customers pay when submitting their intake for clinical review. Payment does not guarantee medication, while the terms describe consultation, review and administrative fees as nonrefundable upon submission. That sequence makes the checkout decision more consequential than a simple request to learn whether treatment is available. Before paying, a prospective customer needs to understand what the payment buys, what can be retained and what happens if the clinician declines.

AHC documents an online service offering compounded semaglutide and tirzepatide, including separate microdose programs. Its public pages describe clinical review, affiliated pharmacies, refrigerated shipping and support-mediated treatment questions. They also leave important gaps around recurring charges, cancellation and rejected orders, with inconsistent descriptions of consultation fees and included services. This review examines the public documentation consulted October 19, 2026, focusing on the commitments a U.S. adult would be asked to make—not endorsing treatment or independently verifying AHC’s licensing and accreditation claims.

At a glance

Advertised standard-program prices: Compounded semaglutide with B12 starts at $129 per month; compounded tirzepatide with B12 starts at $169 per month. Both are described as weekly subcutaneous injections, with each vial designed for 28 days.
Sources: [6] [9]
Payment precedes approval: The semaglutide intake requires payment on submission. A licensed clinician subsequently reviews the order and may approve or decline it.
Sources: [6]
Refund restrictions begin early: The terms call consultation, medical-review and administrative-processing fees nonrefundable upon submission, with all charges nonrefundable after review is completed or pharmacy fulfillment begins.
Sources: [11]
Microdose programs have separate conditions: Semaglutide and tirzepatide microdose programs are each advertised at $99 per month. A dedicated intake is required, including for existing patients, and the microdose page says availability does not extend to all 50 states.
Sources: [10] [4]
Affiliated-pharmacy pricing: AHC’s terms direct customers to affiliated pharmacies and warn that prices through another pharmacy may be higher and are outside AHC’s control.
Sources: [11]

The first commitment is a paid review, not a guaranteed prescription

The terms identify the business as Alternate Health Club, LLC, doing business as Alternate Health Club. AHC says independently contracted, U.S.-licensed clinicians provide clinical services and may approve or decline an order after individual review. Completing an assessment alone does not establish a doctor-patient relationship. These distinctions matter because the company collecting an order, the clinician deciding on treatment and the pharmacy dispensing medication have different responsibilities.

On the semaglutide product page, the sequence is explicit: complete the intake, pay on submission and wait for a licensed clinician’s decision. If approved, instructions arrive by email and medication ships through cold-chain express delivery. The page says no video call is required in this standard flow. If declined, AHC support will contact the customer, but the consulted documentation does not specify the amount retained or returned after that decision.

AHC limits site use and registration to adults 18 and older; that is not a complete medication-eligibility policy. The pages do not establish comprehensive clinical thresholds or laboratory requirements. A useful application of our enrollment-terms checklist is to ask AHC for the rejected-order refund breakdown before submitting payment, rather than assuming that clinical ineligibility automatically reverses every charge.

Sources: [11] [5] [6]

What the advertised prices do—and do not—purchase

AHC advertises compounded semaglutide with vitamin B12 from $129 per month and compounded tirzepatide with B12 from $169 per month. Both product descriptions specify weekly subcutaneous injections and vials designed to cover 28 days. That supply description is not identical to a calendar month. The starting-price language also matters: a customer should obtain the actual checkout amount for the prescribed product rather than treating the headline as an unconditional quote.

The semaglutide page says the same monthly rate applies at every dosage tier, with no membership fee. It lists intake review, a treatment plan, a prescription when medically appropriate and cold-chain express shipping as included. Optional services are separate. A direct clinician consultation costs $29.99 on that page, and ondansetron ODT is described as separately available optional support. The documentation does not establish that needles and all other supplies accompany every order.

The microdose listing separately advertises semaglutide and tirzepatide at $99 per month each. Those are distinct offerings, not proof that standard treatment costs $99. AHC’s general pages and calculators contain conflicting messages about consultation charges and inclusions. Ask for one itemized written quote identifying the product, review fee, shipping, supplies and optional services, particularly if a general statement that everything is included differs from the selected product page.

AHC’s advertised charges and the conditions to clarify
Offering	Documented price	Important boundary
Compounded semaglutide with B12	From $129 per month	Weekly subcutaneous injection; vial designed for 28 days; clinical approval required
Compounded tirzepatide with B12	From $169 per month	Weekly subcutaneous injection; vial designed for 28 days; clinical approval required
Semaglutide microdose program	$99 per month	Separate microdose intake required; state availability must be confirmed
Tirzepatide microdose program	$99 per month	Primarily described for maintenance and stability, not active weight loss
Optional direct clinician consultation	$29.99	Listed on the semaglutide page for consultation before or during treatment

Sources: [6] [9] [10] [8] [7]

Automatic shipments are documented; cancellation mechanics are not

AHC’s general FAQ says customers automatically receive monthly medication shipments according to their prescription after visits, and that only one month is shipped at a time. Its weight-management page separately says refills depend on the clinician’s assessment and ongoing plan. Together, these statements describe continuing fulfillment subject to clinical authorization. They do not establish the precise date of a recurring charge, the consent used to authorize it or the cutoff for stopping the next order.

The consulted documentation does not detail a cancellation procedure, minimum notice period, minimum commitment or specific prepaid package. Nor does a monthly advertised price resolve those questions. Our guide to billing intervals and ongoing commitments explains why the price label, supply period and renewal mechanism should be checked separately. For AHC, ask which action cancels future shipments and which action stops future charges, and request written confirmation of both.

The semaglutide page says treatment has no fixed timeline and is reviewed as the patient progresses. That is a description of clinical duration, not a promise of month-to-month cancellation rights. Likewise, AHC’s statement that monthly prices are consistent across dosage tiers should not be read as an indefinite price lock. Before enrollment, obtain the next billing date, refill-review requirements and any policy governing changes to future charges.

Sources: [6] [13] [8]

Refund boundaries start before pharmacy fulfillment

AHC’s terms say consultation, medical-review and administrative-processing fees are earned upon submission and are nonrefundable. They also say review, processing and care coordination begin immediately. Once provider review is completed or pharmacy fulfillment has begun, all fees and charges become nonrefundable under the stated policy. This creates an early financial boundary: an order need not have shipped for the terms to describe the entire charge as nonrefundable.

The semaglutide page separately calls prescription sales final and directs customers who suspect a filling error to support. When refunds are issued, it describes a typical three-to-five-business-day period depending on the bank; that is not a guaranteed bank-arrival deadline. The terms also exclude refunds for shipping delays, carrier problems, weather, missed deliveries, incorrect addresses and package theft. These are AHC’s stated restrictions, not an independent conclusion about their legal enforceability.

There is one specific microdose exception: the semaglutide microdose page promises cancellation and a full refund for orders submitted without the required microdose intake. That narrow promise should not be generalized to clinical rejection or a customer changing their mind. Read AHC’s policy alongside our guide to refund exclusions, and ask which rule governs the exact order status before assuming cancellation will also produce a refund.

Sources: [11] [6] [4]

The pharmacy and shipping terms divide responsibility

AHC says it does not manufacture medication and that licensed U.S. pharmacies dispense it. Its footer describes pharmacy partners as state-licensed and NABP-accredited, while its terms describe affiliates as 503A compounding pharmacies. The consulted documentation does not identify the pharmacy that would fill an individual order or independently verify these credentials. Its affiliated-pharmacy requirement also matters financially: AHC warns that another pharmacy may charge more, with pricing outside its control.

The terms authorize AHC or its agents to take possession of dispensed medication, package it and forward it through a commercial carrier. Another clause assigns the patient responsibility for condition, storage, handling and timely delivery once the medication leaves the dispensing pharmacy and enters AHC’s or its agents’ possession. That allocation deserves attention alongside cold-chain marketing. Our guide to platform, clinician and pharmacy responsibilities offers a framework for asking who resolves each problem.

The semaglutide page lists typical processing of one to two business days and average delivery of four to twelve business days, within the United States only. These are separate estimates, not a clinical-review deadline or guaranteed arrival. AHC says ice packs need not arrive frozen. FDA nevertheless advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated, and contacting the provider or dispensing pharmacy. Ask AHC how it assesses and resolves such deliveries.

Sources: [5] [11] [6] [1]

Access to a clinician needs a clearer service description

AHC’s product-specific and general pages describe different consultation experiences. The semaglutide page says the standard process requires no video call and offers a $29.99 direct consultation before or during treatment. The general weight-management page describes meeting a clinician by phone or video, while saying most people do not require a video booking. Other public messaging describes no consultation charges or invites a free consultation. The documentation does not fully reconcile these descriptions.

For ongoing clinical questions and treatment-change requests, the semaglutide page directs customers through website live chat or email support. It says the medical officer reviews every dosage request and that clinical questions and changes pass through support so a licensed reviewer sees them. This is a documented routing process, not evidence of immediate clinician access. No specific support-response time, clinical-review turnaround or mandatory follow-up schedule is established in the consulted material.

AHC also promotes centralized tracking of refills, shipments and progress. That may help organize the service, but it does not answer how quickly a clinical concern reaches the appropriate professional or whether a particular interaction adds a fee. Before paying, distinguish routine support, included medical review and an optional paid consultation. Obtain the contact route for urgent medication concerns as well as the route for ordinary billing or shipment questions.

Sources: [6] [13] [5] [7] [8]

Microdose enrollment and geography require separate confirmation

AHC’s microdose program is not simply a lower-priced checkout choice within the standard intake. The semaglutide microdose page requires a dedicated form from every customer, including existing patients. It describes compounded semaglutide plus B12 and says prior GLP-1 use is not necessarily required; a licensed clinician determines eligibility from the intake. The tirzepatide microdose page frames that plan primarily around weight maintenance and stability rather than active weight loss.

Geographic claims also differ by page. AHC’s cost calculator advertises shipping to all 50 states, but the microdose listing explicitly says it is not available in all 50. The consulted documentation does not name the excluded states. A prospective microdose customer should confirm availability for the specific product and delivery address before payment, rather than extending the broader national-shipping claim to every program. The same question is useful when changing products or relocating.

Payment options need similar precision. AHC says many patients may be able to use HSA or FSA funds, depending on their plan and confirmation with its administrator. That statement does not establish insurance acceptance, insurer billing or coverage for an individual prescription. Neither the $99 microdose price nor a possible account-payment option settles the final amount payable, the clinical decision or the rules for future orders.

Sources: [10] [12] [4] [7]

Product status and data permissions are part of informed enrollment

AHC acknowledges that its compounded medications are not FDA approved and says they are prescribed only when a clinician determines commercial options cannot meet the patient’s needs. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and state-licensed pharmacy. Compounded preparations do not undergo FDA premarket review for safety, effectiveness and quality. Nonapproval alone, however, does not establish clinical inequivalence or independently validate or condemn AHC.

AHC separately lists ondansetron ODT, sumatriptan, rizatriptan and albuterol HFA as FDA-approved, noncompounded medications dispensed after review. Those product distinctions should not be converted into an FDA endorsement of AHC or its GLP-1 blends. Likewise, published research on branded medicines does not establish outcomes for AHC’s compounded formulations or microdose programs. A clear contract can explain what is purchased; it cannot substitute for evidence about the particular treatment.

The terms also authorize affiliated pharmacies to share prescription information, dispensing status, shipping records and identity-verification details with AHC. The authorization lasts 12 months or until written revocation. Privacy language elsewhere in the terms sits uneasily alongside the site’s HIPAA-related links and protected-information authorization, so this review cannot confirm compliance. Ask how to revoke the authorization, what information remains necessary for outstanding orders and where to obtain the applicable privacy documentation before enrollment.

Sources: [5] [11] [1] [2] [3]

Questions & answers

Does paying AHC guarantee a prescription?

No. The semaglutide page says payment submits the order for clinical review only. A licensed clinician retains discretion to approve or decline it, and support contacts customers after a rejection. The documentation does not specify the exact refund calculation for a declined order, while the terms describe several submission-related fees as nonrefundable.

Sources: [6] [11]

Is a clinician conversation included in AHC’s monthly price?

The documentation is inconsistent. The semaglutide page includes clinical intake review but lists a direct clinician consultation at $29.99. General pages describe phone or video encounters, while other messaging refers to free consultations or no consultation charges. Confirm which interaction your order includes and whether a requested conversation creates a separate charge.

Sources: [6] [13] [7]

How do I stop AHC’s next shipment or charge?

The consulted pages do not provide a clear cancellation method, renewal cutoff or recurring-charge schedule. The general FAQ does describe automatic monthly shipments subject to the prescription. Ask support for the next charge date and the deadline to stop fulfillment, then obtain written confirmation. Stopping future service does not necessarily refund an order already under review.

Sources: [8] [11]

Can existing AHC patients order microdoses without another intake?

No. The semaglutide microdose page requires the dedicated Microdosing Intake Form from all customers, including existing patients. It promises cancellation and a full refund when that form is missing. Previous GLP-1 treatment is not described as a universal prerequisite; eligibility remains a clinician’s decision. Confirm state availability because the microdose listing excludes some states without naming them.

Sources: [4] [10]

What if an AHC injection delivery arrives warm?

FDA advises not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. AHC’s statement that ice packs need not remain frozen does not resolve whether medication was adequately refrigerated. Contact support about the shipment and ask for pharmacy involvement; the terms contain broad delivery-related refund exclusions.

Sources: [1] [6] [11]

Can I use a different pharmacy or pay through insurance?

AHC’s terms direct customers to affiliated pharmacies and warn that another pharmacy may cost more. The consulted documentation does not confirm insurance acceptance, insurer billing or individual coverage. Its HSA/FSA statement is conditional on the customer’s plan. Ask separately about prescription-transfer arrangements, outside-pharmacy pricing and payment documentation rather than treating those questions as interchangeable.

Sources: [11] [7]

Our assessment

AHC documents several useful specifics: product-level starting prices, B12 formulations, 28-day vial descriptions, clinical discretion, an optional consultation price and explicit refund restrictions. Its shortcomings are concentrated where a customer needs certainty before payment: the rejected-order refund amount, recurring-charge authorization, cancellation cutoff, exact inclusions and responsibility for delivery problems. Consultation and geographic inconsistencies add reasons to obtain product-specific written answers. The practical next step is not to assume either a risk-free trial or an unavoidable long-term commitment; neither is established by the consulted documentation. Request the full current terms, an itemized quote and written cancellation and rejected-order policies before submitting a paid intake. Those answers would improve contractual clarity, but would not independently verify pharmacy credentials or establish clinical results.

Visit Alternate Health Club (AHC)’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Alternate Health Club Review: What Payment Starts—and What Its Terms Leave Open

At a glance

01The first commitment is a paid review, not a guaranteed prescription

02What the advertised prices do—and do not—purchase

03Automatic shipments are documented; cancellation mechanics are not

04Refund boundaries start before pharmacy fulfillment

05The pharmacy and shipping terms divide responsibility

06Access to a clinician needs a clearer service description

07Microdose enrollment and geography require separate confirmation

08Product status and data permissions are part of informed enrollment